Market Capitalization (Millions $) |
58 |
Shares
Outstanding (Millions) |
45 |
Employees |
- |
Revenues (TTM) (Millions $) |
- |
Net Income (TTM) (Millions $) |
-4 |
Cash Flow (TTM) (Millions $) |
-84 |
Capital Exp. (TTM) (Millions $) |
0 |
Avrobio Inc
Avrobio Inc is a clinical-stage gene therapy company that specializes in the development of transformative ex vivo lentiviral gene therapies to treat a range of rare genetic diseases. The company's approach involves taking a patient's own cells, modifying them with a lentivirus to insert a functional gene, and then re-infusing these modified cells back into the patient's body.
Avrobio's gene therapies aim to address the root cause of genetic diseases by providing long-lasting and potentially curative treatments. They focus on inherited, lysosomal storage disorders such as Fabry disease, Gaucher disease, and cystinosis, among others. These disorders result from the defective functioning of specific enzymes, leading to the accumulation of toxic substances in cells throughout the body.
The company's lead candidate, AVR-RD-01, is being studied for the treatment of Fabry disease, an inherited disorder that leads to the accumulation of fatty substances in various organs. Avrobio is also actively advancing other programs in its pipeline.
Avrobio utilizes a clinical-stage gene therapy platform called plato', which includes proprietary vectorization and drug product technologies. The company aims to optimize and streamline the manufacturing process of gene therapies to make them more accessible and affordable for patients.
By focusing on rare diseases with high unmet medical need, Avrobio aims to provide innovative solutions that offer transformative outcomes for affected individuals and their families.
Company Address: 100 Technology Square Cambridge 2139 MA
Company Phone Number: 914-8420 Stock Exchange / Ticker: NASDAQ AVRO
AVRO is expected to report next financial results on March 22, 2024. |
|
|